Biomarin Pharmaceutical (BMRN) Total Debt Growth (3y) (2013 - 2025)
Powered by 
Analysis
Biomarin Pharmaceutical (BMRN) Total Debt Growth (3y) (2013 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.08% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.52% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.76% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.30% |
| 10 | Biomarin Pharmaceutical | 12.88 Bn | 12.01 Bn | 786.91 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 234.71% |
| Jun 30, 2024 | 148.59% |
| Mar 31, 2024 | 152.22% |
| Sep 30, 2023 | 9.65% |
| Dec 31, 2022 | -64.69% |
| Sep 30, 2022 | 41.45% |
| Jun 30, 2022 | 44.51% |
| Mar 31, 2022 | -12.35% |
| Dec 31, 2021 | -18.81% |
| Sep 30, 2021 | -49.78% |
| Jun 30, 2021 | -55.95% |
| Mar 31, 2021 | -56.94% |
| Sep 30, 2020 | 77.40% |
| Jun 30, 2020 | 88.69% |
| Mar 31, 2020 | 100.71% |
| Dec 31, 2019 | 91.50% |
| Sep 30, 2019 | -41.02% |
| Jun 30, 2019 | -40.79% |
| Mar 31, 2019 | -0.82% |
| Dec 31, 2018 | 19.40% |